首页 News 正文

Holding the 'miracle drug for weight loss', Novo Nordisk generates 133.4 billion DKK in revenue in H1 2024

youki676
1250 0 0

On August 7, 2024, Novo Nordisk released its financial report for the first half of 2024, with operating revenue of 133.4 billion Danish kroner (DKK), equivalent to 19.5 billion US dollars, a year-on-year increase of 24%; Net profit was 45.5 billion Danish kroner, equivalent to 6.65 billion US dollars, a year-on-year increase of 16%. Among them, the sales revenue of semaglutide is nearly 13 billion US dollars, just one step away from the throne of the drug king.
In addition, Novo Nordisk has revealed that its Phase III OASIS 4 study on weight loss with oral semaglutide Rybelsus (25mg) has been successfully completed. From the perspective of the domestic market, there are currently four GLP-1 receptor agonists approved for weight loss indications, and multiple GLP-1 RA products are in the stage of market application or clinical phase III for weight loss indications, with a focus on the relevant developments in biotechnology and other concepts.
Related ETFs: Biotechnology ETF (516500), Hang Seng Pharmaceutical ETF (159892)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

youki676 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    3